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LETTER
The pulmonary-proteoliposome as a new therapeutic approach for Coronaviruses
Isidoro Feliciello and Alfredo Procino
Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy
ABSTRACT
We are proposingÂ the use of pulmonary-proteoliposome as a new therapeutic approach for
Coronaviruses. The designed strategy represents a potential treatment to reduce the overall viral load
in the lungs and to help the immune system to successfully stave off the infection.
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The most recent virus to appear, belonging to the family of
coronaviridae, is SARS-CoV-2 (Severe Acute Respiratory
Syndrome Coronavirus 2), which causes the syndrome
COVID-19 (Coronavirus Disease-2019). SARS-CoV-2
mainly invades alveolar epithelial cells, resulting in acute
respiratory distress syndrome that can lead to the death of
infected patients.1 Unfortunately, there are no effective anti-
viral drugs, and developing a vaccine would likely require
years.
To try to overcome these issues, we are proposing
a different strategy aimed to reduce the spread of infections
by offering a synthetic cell-surface-like competitor to the
infectious virus. The competitor works as a bait for the
virus. Viruses, like coronaviruses, infect cells through specific
proteins on their viral surfaces and hook to a specific host cell
membrane receptor. SARS-CoV-2 infection is triggered by the
binding of viral S (spike) protein to the ACE2 receptor,
thereby enabling viral RNA to enter cells.2 In our strategy,
viruses will be distracted by using protocells, such as ‘pulmon-
ary-proteoliposomes,’ as competitors. This is a complex
formed by the fusion of ACE2 and liposomes.3 ACE2-like
membrane proteins of pharmaceutical interest, are usually
obtained from cell lines and combined to Liposomes, which
are in vitro self-assembled small (30 nm to several µm) sphe-
rical vesicles created from cholesterol and natural nontoxic
phospholipids, thus forming a cell membrane-like bilayer.
Liposome vesicles are well known for their potential use as
drug carriers that are released to the targeted tissue; many
studies have demonstrated their safety use for pulmonary
administration of different molecules by inhalation.4 We pro-
pose to create proteoliposomes from phospholipids and gly-
coproteins highly similar to human pulmonary cell
membranes that would be used to bait and inactivate corona-
viruses. Optionally, the lumen of such proteoliposomes can be
filled by a specific drug-like RNase.5 Such proteoliposomes
have limited endocytosis capability and, when taken up into
the cell by endocytosis, their contents will follow the endo-
some-lysosome system for degradation.6 This would offer an
even larger pulmonary-like surface area to infectious viruses
that would facilitate virus-liposome interactions and hence
virus titration away from the cell, thus preserving the lung
tissue from the infection. This approach should, in theory,
reduce the overall viral load of the pulmonary tissue while
helping the immune system to successfully stave off infection.
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